A membrane capture assay for lipid kinase activity

doi:10.1038/nprot.2007.361

Nat Protoc. Author manuscript; available in PMC 2010 August 10.

Published in final edited form as:

Nat Protoc. 2007; 2(10): 2459–2466.

doi: 10.1038/nprot.2007.361

PMCID: PMC2919233

HHMIMSID: HHMIMS216784

A membrane capture assay for lipid kinase activity

Zachary A Knight,^1,⁴ Morri E Feldman,² Andras Balla,³ Tamas Balla,³ and Kevan M Shokat¹

¹Department of Cellular & Molecular Pharmacology, Howard Hughes Medical Institute, University of California, San Francisco, California 94158, USA.

²Graduate Group in Biophysics, University of California, San Francisco, California 94158, USA.

³Endocrinology and Reproduction Research Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA.

Correspondence should be addressed to K.M.S. (Email: shokat/at/cmp.ucsf.edu)

⁴Present address: The Rockefeller University, New York, New York 10021, USA.

The publisher's final edited version of this article is available at Nat Protoc

See other articles in PMC that cite the published article.

Abstract

Phosphoinositide kinases such as PI3-kinase synthesize lipid second messengers that control diverse cellular processes. Recently, these enzymes have emerged as an important class of drug targets, and there is significant interest in discovering new lipid kinase inhibitors. We describe here a procedure for the high-throughput determination of lipid kinase inhibitor IC₅₀ values. This assay exploits the fact that phosphoinositides, but not nucleotides such as ATP, bind irreversibly to nitrocellulose membranes. As a result, the radiolabeled lipids from a kinase assay can be isolated by spotting the crude reaction on a nitrocellulose membrane and then washing. We show that diverse phosphoinositide kinases can be assayed using this approach and outline how to perform the assay in 96-well plates. We also describe a MATLAB script that automates the data analysis. The complete procedure requires 3–4 h.

INTRODUCTION

Signaling by lipid kinases

Phosphatidylinositol (PI) is an abundant component of all eukaryotic cell membranes. In response to upstream signals, lipid kinases phosphorylate PI at specific positions on the inositol head group to generate a spectrum of lipid second messengers (Fig. 1). These differentially phosphorylated lipids bind to and regulate the activity of diverse effector proteins, including protein kinases, ion channels, guanine-nucleotide exchange factors, phospholipases and adaptor proteins. In this way, lipid kinases are able to control a wide range of cellular processes.

Figure 1

Routes for the synthesis of phosphoinositides in mammalian cells. Lipid kinases are shown in red and lipid phosphatases are shown in blue.

Recent interest in phosphoinositide signaling has been driven by studies of the class I PI3-kinases (p110α, p110β, p110δ and p110γ). These enzymes are activated by receptor tyrosine kinases and G-protein-coupled receptors to phosphorylate phosphatidylinositol-4,5-bisphosphate (PI(4,5)P₂), thereby generating the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP₃; Fig. 1). PIP₃ acts as a docking site at the plasma membrane for signaling proteins that include the protein kinases 3-phosphoinositide-dependent protein kinase-1 (PDK1) and Akt; these kinases are activated by PIP₃ to promote nutrient uptake, suppress apoptosis and drive cell proliferation¹. PI3-kinase signaling is antagonized by PTEN², a lipid phosphatase that dephosphorylates PIP₃ to generate PI(4,5)P2. The PI3-kinase pathway is frequently activated in solid tumors, and mutations in p110α, Ras (an upstream PI3-kinase activator³^–⁵) and PTEN are among the most common genetic alterations in cancer⁶^–⁹. In addition, there is considerable evidence that p110δ and p110γ may be useful targets for the treatment of inflammation and autoimmune diseases¹⁰^–¹⁵. Together, these observations have stimulated widespread interest in identifying selective PI3-kinase inhibitors¹⁶.

In addition to the well-characterized class I PI3-kinases, several other families of lipid kinases have been identified (Fig. 1). These include the class II and III PI3-kinases, which synthesize phosphatidylinositol-3-phosphate (PI(3)P) and phosphatidylinositol-3,4-bisphosphate (PI(3,4)P₂); two families of PI4-kinases (designated type II and type III) that phosphorylate PI to generate phosphatidylinositol-4-phosphate (PI(4)P); and a family of phosphatidylinositol phosphate kinases (PIP-kinases) that synthesize primarily PI(4,5)P₂. Furthermore, these lipid kinases are antagonized by phosphatases that dephosphorylate specific positions on the inositol ring (Fig. 1). Together, these lipid kinases and phosphatases coordinate the synthesis of a complex pool of second messengers that regulate diverse aspects of cell biology.

Lipid kinase assays

Purified lipid kinases are assayed in vitro to characterize their enzymatic properties or identify small molecule inhibitors. Traditionally, lipid kinase activity has been assayed by monitoring phosphate transfer to lipid via thin-layer chromatography (TLC). In this approach, the kinase is allowed to phosphorylate lipid in the presence of [γ-³²P]ATP; radiolabeled lipids are separated from [γ-³²P]ATP by extracting into organic solvent followed by TLC; and the radioactivity in isolated TLC spots is detected by phosphorimaging or scintillation counting. This approach is highly sensitive, as phospholipid isomers are chromatographically separated from each other as well as from residual ATP. A limitation of this assay, however, is that it is labor intensive and of low-throughput due to the need for extraction and TLC steps. Recently, fluorescence-based assays for the class I PI3-kinases have been developed that overcome some of these difficulties through the use of protein domains that bind to PIP₃ (ref. ¹⁷).

We have initiated an effort to discover pharmacological inhibitors of specific lipid kinases and characterize the selectivity of these molecules across the lipid kinome¹⁸^,¹⁹. To this end, we have developed a simple lipid kinase assay to facilitate the high-throughput determination of lipid kinase inhibitor IC₅₀ values on a laboratory scale. This assay exploits the fact that phosphoinositides, but not nucleotides such as ATP, bind irreversibly to nitrocellulose membranes through hydrophobic interactions. As a result, it is possible to isolate the radiolabeled lipids from a kinase assay by spotting the crude reaction on a nitrocellulose membrane and then washing (Fig. 2). Using this approach, we have assayed diverse lipid kinases in a single format and determined several thousand inhibitor IC₅₀ values.

Figure 2

Outline of the membrane capture lipid kinase assay.

We also describe here a MATLAB script (‘Spot’) that automates the analysis of phosphorimager data from this assay. By using this script, hand-spotted radioactivity can be counted quickly, uniformly and with minimal user intervention. The script, which utilizes MATLAB’s image analysis and statistics toolboxes, is available as MATLAB source code or as compiled executables for mac and pc platforms from http://www.ucsf.edu/shokat/SPOT.htm.

Assay validation

We have previously reported the profiling of lipid kinase inhibitors using this assay¹⁸. We describe here representative data illustrating features of this approach. Ten lipid kinases were assayed against a panel of phosphoinositides to characterize their lipid substrate specificity (Fig. 3). The observed substrate preferences in this assay closely mirror the reported biochemical selectivities of these enzymes. The three PI4-kinases each utilize exclusively PI as a substrate²⁰^–²³. The PIP-kinases PI(4)P5-KIα and PI(4)P5-KIβ preferentially phosphorylate PI(4)P, whereas PI(5)P4-KIIβ phosphorylates PI(5)P²⁴^–²⁶. The class I PI3-kinases (p110α, p110β, p110δ and p110γ) phosphorylate either PI or PI(4,5)P₂ in a ratio that varies across the four isoforms. PI(4,5)P₂ is the primary substrate of these enzymes in vivo, but PI is used preferentially in vitro under many assay conditions. The relative phosphorylation of these two substrates in vitro is known to depend on the identity and composition of other lipids in the membrane bilayer²⁷. Overall, these data show that diverse lipid kinases that preferentially utilize at least four different phosphoinositide substrates can be assayed using the membrane capture approach.

Figure 3

Substrate specificity of lipid kinases. Kinases were incubated in the appropriate reaction buffer with [γ-³²P]ATP (5 µCi per each 50 µl reaction), nonradioactive ATP (10 µM), BSA (0.5 mg ml⁻¹) and each phosphoinositide (more ...)

Signal strength in this assay depends on length of time that the kinase reaction is allowed to proceed and the amount of enzyme used (Fig. 4). We have not observed saturation of the phosphoinositide binding capacity of nitrocellulose under the assay conditions described here, although, as in any enzymatic assay, it is possible to deplete substrate at sufficiently high enzyme concentrations. The optimal concentration of kinase for this assay depends on the specific activity of the enzyme under the conditions used, and this varies greatly across lipid kinases (see General assay considerations).

Figure 4

The membrane capture assay of PI(5)P4-KIIβ is linear with respect to time and enzyme concentration. (a) PI(5)P4-KIIβ (0.12 mg ml⁻¹) was assayed in 25 mM HEPES (pH 7.4), 10 mM MgCl₂ with [γ-³²P]ATP (5 µCi per reaction), (more ...)

Figure 5 depicts typical data for the determination of IC₅₀ values of two inhibitors (PIK-108 and PIK-93) against a lipid kinase (p110α). In this experiment, inhibitor was arrayed in 5 µl of 10% DMSO across eight rows of a 96-well PCR plate; PCR plates are used to facilitate handling small reaction volumes (25 µl), thereby minimizing the consumption of kinase and [γ-³²P]ATP. The inhibitor was aliquoted in threefold dilutions to achieve final assay concentrations that range from 50 to 0.0003 µM, thereby spanning the predicted IC₅₀ value for the drug. Kinase was then added to each well of the plate in 10 µl of a solution containing kinase reaction buffer, lipid and BSA. To initiate the kinase reaction, 10 µl of a solution containing 2 µCi [γ-³²P]ATP was added to each well of the plate (adjusted to achieve a final ATP concentration of 10 µM in the assay). The kinase reaction was allowed to proceed for 30 min, at which point the reaction was terminated by spotting 4 µl from each well onto a nitrocellulose membrane. All liquid transfers were performed using a multi-channel pipettor to initiate and terminate the assay consistently. The membrane was then washed four times for 15 min each with 100–200 ml of wash solution (1 M NaCl/1% phosphoric acid). The last wash was allowed to proceed overnight. After allowing the membrane to dry, it was exposed to a phosphorimager screen to generate the raw data shown in Figure 5b. Quantification of these spots using the MATLAB script ‘Spot’ was performed as shown in Figure 6 to yield the dose–response data shown in Figure 5a. IC₅₀ values for each inhibitor were obtained by fitting a sigmoidal dose–response curve to these data using the Prism software package.

Figure 5

Determination of IC₅₀ values for p110α with the PI3-kinase inhibitors PIK-108 and PIK-93 using the membrane capture assay. (a) Quantitated dose–response data for each compound. Y axis represents arbitrary relative PI3-K activity. IC₅₀ (more ...)

Figure 6

‘Spot’ image analysis tool. Screenshot depicting the analysis of dose–response data from Figure 5 using the MATLAB image analysis script Spot. Automatic location, refinement and integration of radioactive spots were accomplished (more ...)

General assay considerations

The specific activity of the lipid kinase is the major determinant of the signal-to-background ratio in this assay. Extended washing removes the vast majority of radioactive ATP and phosphate from the nitrocellulose membrane, but trace amounts of radioactive material will adhere to the membrane independent of kinase activity. For relatively active lipid kinases such as the class I PI3-kinases or the PI4-kinases, we have found that a final kinase concentration in the assay of ~ 1 µg ml⁻¹ (~ 5 nM) typically yields a signal-to-background ratio greater than 10. At this concentration, ~ 2 µg of enzyme is sufficient to assay a 96-well plate, which is cost efficient for most purposes. Other lipid kinases, such PI(5)P4-KIIβ, have very low specific activity under all assay conditions we have tested, and for these kinases it may be necessary to use 50- to 100-fold more enzyme to achieve similar results. Similar considerations apply to the analysis of kinase activity from immunoprecipitates. However, as the 96-well assay format described below requires a homogenous source of enzyme, immunoprecipitated kinases must be eluted from the beads before assaying in 96-well plates.

For each kinase preparation, it is necessary to empirically determine the appropriate enzyme concentration before starting high-throughput assays. As a general guideline, one should aim for a radioactive signal that is at least tenfold greater than negative controls in which either the kinase or the lipid has been omitted. During the optimization of enzyme concentration, it is also advisable to test several different reaction lengths (e.g., 30, 60 and 120 min) to assess the stability of the enzyme and the potential for enhanced signal-to-background ratio at longer reaction times.

The signal-to-background ratio in this assay is largely independent of the concentration of radioactive ATP, because the signal and background are both expected to increase as the concentration of radioactive ATP is increased (the background is caused by radioactivity adhering nonspecifically to the nitrocellulose membrane). The concentration of radioactive ATP primarily determines the overall signal strength of the assay and, therefore, the length of time that the membrane must be exposed to the phosphorimager screen. We typically use a radioactive ATP concentration of 0.1 Ci µl⁻¹ with a total ATP concentration of 10 µM. If desired, the radioactive ATP concentration can be decreased at least fivefold without impairing the assay. [γ-³³P]ATP can also be substituted for [γ-³²P]ATP.

The ATP concentration used in this assay influences the IC₅₀ value that is measured for a kinase inhibitor. For an ATP competitive kinase inhibitor, the IC₅₀ value is related to the K_i of the inhibitor, the K_M,ATP of the kinase and the ATP concentration by the Cheng–Prusoff equation²⁸^,²⁹: IC₅₀ = K_i(1 + [ATP]/K_M,ATP). At ATP concentrations below the K_M,ATP of the kinase, the IC₅₀ value approximates the K_i. At ATP concentrations above the K_M,ATP of the kinase, the measured IC₅₀ value exceeds the K_i. The K_M,ATP has been reported for many protein and lipid kinases²⁸. Because the intracellular ATP concentration is 1–5 mM³⁰^,³¹, most kinase inhibitors appear less potent in cells than when assayed at lower ATP concentrations (typically 10–100 µM) in vitro.

The source and physical form of the lipids used for the assay can be important in some cases. Commercially available phosphoinositides may be purified from natural sources or synthesized chemically. We have found that both natural and synthetic lipids are compatible with the membrane capture assay, although in some cases natural lipids are less expensive. Synthetic lipids are often available in several hydrocarbon lengths (e.g., C8 and C16); we recommend using the longer hydrocarbons to ensure irreversible binding to the nitrocellulose membrane. The purity of commercial phosphoinositides is variable, and impurities in commercial preparations have led to the misassignment of lipid kinase substrate specificity²⁶. For experiments in which the purity of the phosphoinositide is critical, commercial phosphoinosites should be independently characterized by HPLC or TLC. In this respect, the membrane capture assay does not distinguish between different phosphoinositides that may be generated by a kinase that phosphorylates a single lipid at multiple sites. These considerations are less relevant for the determination of inhibitor IC₅₀ values using well-characterized lipid kinases.

The protocol outlined below describes how to perform lipid kinase assays in either individual microcentrifuge tubes or 96-well plates. The former protocol is appropriate for determining the optimal enzyme concentration and troubleshooting the assay. The 96-well plate procedure facilitates the rapid determination of inhibitor IC₅₀ values.

MATERIALS

REAGENTS

Purified lipid kinase. Class I PI3-kinases are commercially available (Upstate). Other lipid kinases can be expressed and purified using published techniques
Purified phosphoinositides (Avanti Polar Lipids, Sigma)
1:1 dioleoyl phosphatidylserine/dioleoyl phosphatidylcholine (DOPS/DOPC) carrier lipid (Avanti Polar Lipids)
Tris (Sigma)
MgCl₂ (Sigma)
Nitrocellulose (Bio-Rad)
Phosphoric acid (Sigma) Phosphoric acid is corrosive.
NaCl (Sigma)
ATP (Sigma)
[γ-³²P]ATP (Perkin-Elmer) Radioactive. Suitable screening should be used.
96-well assay plates (VWR, cat. no. 82006-636)
96-well plate covers (Eppendorf, cat. no. 3211-360)
PCR tube strips as reagent reservoirs (VWR, cat. no. 20170-0074)
PCR tube holder (VWR, cat. no. 80086-084)

EQUIPMENT

Multichannel pipettors (Finnpipette; Thermo Fisher)
Water bath sonicator (VWR, cat. no. 50HT)
Phosphorimager (GE Healthcare)
Rocking platform (VWR, cat. no. 40000-300)
Heat lamp (optional) (Fisher, cat. no. 11-504-50)

REAGENT SETUP

10× kinase assay buffer (all kinases except PI4-Ks and VPS34) 250 mM HEPES (pH 7.4) and 100 mM MgCl₂.
10× kinase assay buffer for VPS34 500 mM Tris (pH 8.0) and 200 mM MnCl₂. Add MnCl₂ immediately before use.
10× kinase assay buffer for PI4-Ks 500 mM Tris (pH 7.4), 200 mM MgCl₂ and 4% (vol/vol) Triton X-100.
10× lipid stock solution for PI Suspend the solid PI in water to a final concentration of 1 mg ml⁻¹. Sonicate in a water bath sonicator for 20 s to generate lipid vesicles. This solution can be stored at 4 °C for at least 1 month. PI can also be assayed in the presence of DOPS/DOPC (below) if desired.
10× lipid stock solution for all other phosphoinositides Prepare a 1mg ml⁻¹ solution of the carrier lipids DOPS/DOPC (1:1). Sonicate this solution in a water bath sonicator for 20 s. Suspend the solid phosphoinositide in this solution to a final concentration of 1 mg ml⁻¹. Sonicate this solution in a water bath sonicator for 20 s to generate lipid vesicles. This solution can be stored at 4 °C for at least 1 month.
100× BSA stock solution Prepare a 50 mg ml⁻¹ solution of BSA in water. This can be stored in frozen aliquots at −20 °C indefinitely.
1,000× ATP stock solution Prepare a 10 mM solution of ATP in 25 mM Tris (pH 7.4) and 10 mM EDTA. This can be stored in frozen aliquots at −20 °C for at least 1 year.
2.5× buffer–substrate solution On the day of the assay, prepare a 2.5 × solution containing kinase buffer, lipid and BSA by mixing 10× kinase assay buffer, 10× lipid stock solution and water in a 1:1:2 ratio by volume. Dilute the 100× BSA stock solution 40-fold into this solution. Store this buffer–substrate on ice.
2.5× ATP solution On the day of the assay, prepare a 2.5× ATP solution by diluting 1,000× ATP stock solution 400-fold into water. Add [γ-³²P]ATP to a final concentration of 0.1–0.25 µCi µl⁻¹. Store this diluted ATP solution on ice. This solution is radioactive. Follow appropriate safety procedures for handling ³²P.
Membrane wash solution 1 M NaCl/1% phosphoric acid.

PROCEDURE

Preparing the assay An external file that holds a picture, illustration, etc.
Object name is nihms216784ig2.jpg

1–2 h

Prepare the stock solutions described above.
Cut a rectangular piece of nitrocellulose to a size that will fit in a washbasin. Lids from P-1000 pipette tip boxes make convenient washbasins for this assay and accommodate nitrocellulose membranes of approximately 12 cm × 8.5 cm.
Mark the nitrocellulose membrane with a pencil to indicate where the kinase reactions will be spotted. Follow option A for assays in individual microcentrifuge tubes and option B for assays in 96-well plates.
- Assays in individual microcentrifuge tubes
  - Place numbered marks on the membrane at least 1 cm apart. A total of 12–15 marks can be conveniently placed on a 12 cm × 8.5 cm membrane.
- Assays in 96-well plates
  - Mark the upper left-hand corner of the membrane with a pencil. Use this mark to orient the membrane with respect to the 96-well assay plate after the kinase reactions have been spotted.
Aliquot inhibitor to each kinase reaction. The final concentration of DMSO in the assay should not exceed 2%. Follow option A for assays in individual microcentrifuge tubes and option B for assays in 96-well plates.
- Assays in individual microcentrifuge tubes
  - Label the appropriate number of microcentrifuge tubes.
  - For a final reaction volume of 50 µl, aliquot 10 µl of inhibitor in 10% DMSO to each tube in this step. If not testing any inhibitors, aliquot 10 µl of water instead.
- Assays in 96-well plates
  - Prepare a 5× 96-well stock plate containing serial dilutions of the inhibitors to be tested in 10% DMSO. These plates can be stored at −20 °C.
  - For a final reaction volume of 25 µl, transfer 5 µl of inhibitor in 10% DMSO to each well of a 96-well assay plate. Use a 96-well PCR plate as the assay plate to facilitate handling 25 µl reaction volumes.
Prepare the 2.5× buffer–substrate and ATP solutions described above. Determine the appropriate volume of each by multiplying the number of kinase reactions by 20 µl (for assays in microcentrifuge tubes) or 10 µl (for assays in 96-well plates) and then adding at least 10% extra to account for sample losses during pipetting. Store these solutions on ice.
Dilute the appropriate amount of kinase into freshly made 2.5× diluted kinase assay buffer. Store on ice. For the class I PI3-kinases, a final enzyme concentration of ~ 1 µg ml⁻¹ in the assay is a good starting point.
Aliquot the enzyme–buffer–substrate solution to each reaction. Follow option A for assays in individual microcentrifuge tubes and option B for assays in 96-well plates.
- Assays in individual microcentrifuge tubes
  - For a final reaction volume of 50 µl, aliquot 20 µl of enzyme–buffer–substrate solution to each tube. Mix by tapping the tube.
- Assays in 96-well plates
  - Place a strip of 12 PCR tubes in a PCR tube holder. This will serve as a reservoir for transferring the enzyme–buffer–substrate solution to the assay plate with a multichannel pipettor.
  - Aliquot enzyme–buffer–substrate solution to each of the PCR tubes. Calculate the amount of solution needed by multiplying the number of rows being assayed by 10 µl. For example, a single 96-well plate requires at least 80 µl of solution per PCR tube. Always include at least 10% extra solution in the reservoir to account for sample loss during transfer.
  - Transfer 10 µl of solution to each well of the assay plate using a multichannel pipettor. Mix by pipetting up and down five times.

Performing the kinase reaction An external file that holds a picture, illustration, etc.
Object name is nihms216784ig2.jpg

~ 1 h

8
Start the assay by adding the 2.5× ATP solution to each reaction. Allow the reaction to proceed for 30 min or for designated length of time before terminating in Step 11. Follow option A for assays in individual microcentrifuge tubes and option B for assays in 96-well plates.
- Assays in individual microcentrifuge tubes
  - Add 20 µl of the diluted ATP solution to each tube and mix by tapping.
    From this point onward, the procedure involves radioactive components. Take appropriate precautions.
- Assays in 96-well plates
  - Place a strip of 12 PCR tubes in a PCR tube holder. This will serve as a reservoir for transferring the 2.5× ATP solution to the assay plate with a multichannel pipettor.
  - Aliquot 2.5× ATP solution to each of the PCR tubes. Calculate the amount of solution needed by multiplying the number of rows being assayed by 10 µl. For example, a single 96-well plate requires at least 80 µl of solution per PCR tube. Always include at least 10% extra solution in the reservoir to account for sample loss during transfer.
    From this point onward, the procedure involves radioactive components. Take appropriate precautions.
  - Transfer 10 µl of solution to each well of the assay plate using a multichannel pipettor. Mix by pipetting up and down five times. Tap the plate gently on the bench to ensure that all the liquid collects at the bottom of each well.
9
Place a sheet of plastic wrap on the bench adjacent to the kinase reaction. Place several paper towels on top of the plastic wrap, and then place the marked nitrocellulose membrane on top of the paper towels. These will absorb any radioactivity that passes through the nitrocellulose.
10
Terminate the assay by spotting the reactions onto the nitrocellulose membrane. Follow option A for assays in individual microcentrifuge tubes and option B for assays in 96-well plates.
- Assays in individual microcentrifuge tubes
  - Spot 4 µl from each reaction onto the designated mark on the nitrocellulose membrane. When spotting is complete, allow lipids to adhere to the membrane for an additional 2 min. Discard the remainder of the kinase reactions and the paper towels in an appropriate container for solid ³²P radioactive waste.
- Assays in 96-well plates
  - Spot 4 µl from each well onto the nitrocellulose membrane using a multichannel pipettor. Allow approximately 1 cm between rows of spots. When spotting is complete, allow lipids to adhere to the membrane for an additional 2 min. Discard the remainder of the kinase reactions and the paper towels in an appropriate container for solid ³²P radioactive waste.

Washing the membrane An external file that holds a picture, illustration, etc.
Object name is nihms216784ig2.jpg

2 h to overnight

11
Place the membrane in its own washbasin and add 100–200 ml of wash solution to the basin. Mix with gentle rocking for 30 s and then discard the wash solution in an appropriate container for liquid ³²P radioactive waste.
12
Add 100–200 ml of wash solution to the basin and mix with gentle rocking for 5 min. Discard the wash solution in an appropriate container for liquid ³²P radioactive waste, and then repeat for at least four additional washes. After the third wash, the residual radioactivity removed in the wash is often sufficiently low that it can be disposed of down the sink rather than as radioactive waste.
The final wash can be allowed to proceed overnight if desired.

Imaging the membrane An external file that holds a picture, illustration, etc.
Object name is nihms216784ig2.jpg

~ 1–2 h

13
Remove the membrane and allow it to dry for at least 1 h. Drying can be accelerated by placing the membrane under a heat lamp.
14
Wrap the membrane in plastic wrap to avoid transferring radioactivity to the phosphor screen. Tape the wrapped membrane to the phosphor screen cassette and expose to the screen. The optimal length of exposure will depend on the signal in the assay. Class I PI3-kinases assayed using this procedure typically require approximately 15-min exposures.
15
Scan the phosphor screen using a phosphorimager such as the Storm or Typhoon instruments (GE Healthcare). The intensity of each spot can be quantified by densitometry using the software supplied with the phosphorimager. Alternatively, follow Steps 16–22 to quantify the data using the MATLAB script Spot.
The data can be analyzed later if desired.

Using Spot to quantify the phosphorimager data An external file that holds a picture, illustration, etc.
Object name is nihms216784ig2.jpg

~ 10 min

16
At the MATLAB command, prompt type ‘spot’ to start the software. Use the dialog box to choose an image file for analysis. Typhoon Gel files as well as Tiffs are accepted.
17
The graphical interface is organized by steps to help guide the user. Each step is a set of software buttons and options grouped together within a box. Use the ‘Rotate’ and ‘Flip’ button within ‘Step 1’ to adjust the image orientation.
18
Click on ‘Draw Box’ within ‘Step 2’ and draw a box on the image that only contains the spots to be analyzed. Click on ‘Crop Image’ to focus on the spots to be analyzed.
19
Click on ‘Find Spots’ within ‘Step 3’. If too few spots are found, adjust the rejection slider to a lower value, and if too many are found, move the slider to a higher value. Left click on the image to manually identify a spot. Right click on the edge of an already identified spot to delete it. Left click and hold on a spot identifier to move it.
20
Use the ‘Spot Size’ slider in ‘Step 4’ to adjust the spot size so that the darkest spots are just contained within the spot indicators. Adjust the intensity level of the image to confirm that low-intensity pixels are contained within the spot indicators. Click ‘Refine Spots’ to optimize the location of each spot. If the spots move too far, adjust the ‘Spot Movement’ slider to a lower value and return to Step 19.
21
Before saving the spots, click on the button that best indicates the type of data (Regular Array, Rows of Data or Neither). For data in rows or in a regular array, specify the number of rows. For data in a regular array, also specify whether to number the data by rows or columns and whether to transpose the data before writing it to file. Click ‘Save Spots’ and assign a file name in the dialog box. A tab-delimited text file will be written. If the spots are misnumbered, see the troubleshooting advice in Table 1. After saving the file, the data will also be available on the clipboard.
TABLE 1
Troubleshooting table.
22
To view previously saved spots, first perform Steps 16 and 17 and then press ‘Load Spots’. At the file selection dialog, choose a file created previously at Step 21.

Steps 1–7, preparing the assay: 1–2 h
Steps 8–10, performing the kinase reaction: ~ 1 h
Steps 11 and 12, washing the membrane: 2 h to overnight
Steps 13–15, imaging the membrane: ~ 1–2 h
Steps 16–22, using Spot to quantify the phosphorimager data: ~ 10 min

An external file that holds a picture, illustration, etc.
Object name is nihms216784ig4.jpg

Troubleshooting advice can be found in Table 1.

ANTICIPATED RESULTS

The membrane capture procedure can be used to screen small-molecule inhibitors against many different lipid kinases using a single assay format. The assay is of relatively high-throughput, yet requires no automation. Following the procedure described here, a single technician can expect to comfortably assay approximately ten 96-well plates in a day. As the principles of the assay are simple, many variations are possible for different applications.

ACKNOWLEDGMENTS

Z.A.K. is a Howard Hughes Medical Institute Fellow of the Life Sciences Research Foundation. M.E.F. is an ARCS Foundation Fellow. We acknowledge funding from NIH training grant GM08284. K.M.S. received funding from the Howard Hughes Medical Institute. The research of T.B. and A.B. was supported by the Intramural Research Program of the National Institute of Child Health and Human Development of the National Institutes of Health. We thank James Hurley for the generous gift of PI(5)P4-KIIβ.

Footnotes

Reprints and permissions information is available online at http://npg.nature.com/reprintsandpermissions

References

1. Katso R, et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 2001;17:615–675. [PubMed]

2. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 1998;273:13375–13378. [PubMed]

3. Gupta S, et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell. 2007;129:957–968. [PubMed]

4. Rodriguez-Viciana P, et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell. 1997;89:457–467. [PubMed]

5. Rodriguez-Viciana P, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature. 1994;370:527–532. [PubMed]

6. Samuels Y, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554. [PubMed]

7. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br. J. Cancer. 2006;94:455–459. [PMC free article] [PubMed]

8. Chow LM, Baker SJ. PTEN function in normal and neoplastic growth. Cancer Lett. 2006;241:184–196. [PubMed]

9. Li J, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–1947. [PubMed]

10. Okkenhaug K, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science. 2002;297:1031–1034. [PubMed]

11. Ali K, et al. Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature. 2004;431:1007–1011. [PubMed]

12. Wymann MP, et al. Phosphoinositide 3-kinase gamma: a key modulator in inflammation and allergy. Biochem. Soc. Trans. 2003;31:275–280. [PubMed]

13. Hirsch E, et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science. 2000;287:1049–1053. [PubMed]

14. Camps M, et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 2005;11:924–955. [PubMed]

15. Barber DF, et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 2005;11:933–935. [PubMed]

16. Knight ZA, Shokat KM. Chemically targeting the PI3K family. Biochem. Soc. Trans. 2007;35:245–249. [PubMed]

17. Gray A, Olsson H, Batty IH, Priganica L, Peter Downes C. Nonradioactive methods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts. Anal. Biochem. 2003;313:234–245. [PubMed]

18. Knight ZA, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006;125:733–747. [PMC free article] [PubMed]

19. Knight ZA, et al. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg. Med. Chem. 2004;12:4749–4759. [PubMed]

20. Balla T, et al. Isolation and molecular cloning of wortmannin-sensitive bovine type III phosphatidylinositol 4-kinases. J. Biol. Chem. 1997;272:18358–18366. [PubMed]

21. Meyers R, Cantley LC. Cloning and characterization of a wortmannin-sensitive human phosphatidylinositol 4-kinase. J. Biol. Chem. 1997;272:4384–4390. [PubMed]

22. Nakagawa T, Goto K, Kondo H. Cloning and characterization of a 92 kDa soluble phosphatidylinositol 4-kinase. Biochem. J. 1996;320(Part 2):643–649. [PubMed]

23. Nakagawa T, Goto K, Kondo H. Cloning, expression, and localization of 230-kDa phosphatidylinositol 4-kinase. J. Biol. Chem. 1996;271:12088–12094. [PubMed]

24. Ishihara H, et al. Type I phosphatidylinositol-4-phosphate 5-kinases. Cloning of the third isoform and deletion/substitution analysis of members of this novel lipid kinase family. J. Biol. Chem. 1998;273:8741–8748. [PubMed]

25. Ishihara H, et al. Cloning of cDNAs encoding two isoforms of 68-kDa type I phosphatidylinositol-4-phosphate 5-kinase. J. Biol. Chem. 1996;271:23611–23614. [PubMed]

26. Rameh LE, Tolias KF, Duckworth BC, Cantley LC. A new pathway for synthesis of phosphatidylinositol-4,5-bisphosphate. Nature. 1997;390:192–196. [PubMed]

27. Carpenter CL, et al. Purification and characterization of phosphoinositide 3-kinase from rat liver. J. Biol. Chem. 1990;265:19704–19711. [PubMed]

28. Knight ZA, Shokat KM. Features of selective kinase inhibitors. Chem. Biol. 2005;12:621–637. [PubMed]

29. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973;22:3099–3108. [PubMed]

30. Traut TW. Physiological concentrations of purines and pyrimidines. Mol. Cell. Biochem. 1994;140:1–22. [PubMed]

31. Gribble FM, et al. A novel method for measurement of submembrane ATP concentration. J. Biol. Chem. 2000;275:30046–30049. [PubMed]